EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Valerio Therapeutics's Enterprise Value is €233.80 Mil.
Valerio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.52 Mil. Therefore, Valerio Therapeutics's EV-to-FCF for today is 448.76.
The historical rank and industry rank for Valerio Therapeutics's EV-to-FCF or its related term are showing as below:
FRA:C4X'
s EV-to-FCF Range Over the Past 10 Years
Min: -10.91 Med: -2.74 Max: 501.48
Current: 501.48
During the past 13 years, the highest EV-to-FCF of Valerio Therapeutics was 501.48. The lowest was -10.91. And the median was -2.74.
FRA:C4X's EV-to-FCF is ranked worse than 97.27% of 330
companies
in the Biotechnology industry
Industry Median: 16.33
vs FRA:C4X: 501.48
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Valerio Therapeutics's PE Ratio (TTM) for today is calculated as:
Valerio Therapeutics's share price for today is €0.445.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Valerio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.009.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Valerio Therapeutics EV-to-FCF Related Terms
Valerio Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Valerio Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Valerio Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valerio Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Valerio Therapeutics's EV-to-FCF falls into.
Valerio Therapeutics's current Enterprise Value is €233.80 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Valerio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valerio Therapeutics (FRA:C4X) has a EV-to-FCF of 448.76 as of Jul. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Valerio Therapeutics and its competitors. According to the industry distribution chart, Valerio Therapeutics ranks #321 out of 330 companies in the Biotechnology industry, placing it in the top 97.3%.
Is Valerio Therapeutics' EV-to-FCF too high?
Valerio Therapeutics' current EV-to-FCF is 448.76. The Biotechnology industry median EV-to-FCF is 16.33. Valerio Therapeutics' value of 448.76 is 2648.1% above this industry median. Based on the distribution chart, Valerio Therapeutics ranks #321 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Valerio Therapeutics has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valerio Therapeutics' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valerio Therapeutics ranks #321 out of 330 companies for EV-to-FCF. This places Valerio Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 16.33. Valerio Therapeutics' value of 448.76 is 2648.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.33, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valerio Therapeutics's current EV-to-FCF of 448.76 is 2648.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Valerio Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valerio Therapeutics's current EV-to-FCF is 448.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valerio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Valerio Therapeutics (FRA:C4X) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.45 — trading 535.7% above its estimated fair value. The current EV-to-FCF is 448.76 and 2648.1% above the Biotechnology industry median of 16.33. Valerio Therapeutics' overall GF Score™ is 31/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Valerio Therapeutics (FRA:C4X), the current EV-to-FCF is 448.76 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valerio Therapeutics (FRA:C4X) Overvalued in 2026?
Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued.
The current stock price of €0.45 is trading 535.7% above its estimated GF Value™ of €0.07.
GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:C4X:
EV-to-FCF: 448.76
GF Value™: €0.07 vs. price of €0.45 (535.7% above fair value)
Industry Position: 2648.1% above the Biotechnology median (#321 of 330)
No single metric tells the full story. See the FRA:C4X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
31GF Score
Get the complete analysis for FRA:C4X
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:C4X has been successfully added to your 
